AnimaBiotech
Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation
Translation Control Discovery Platform
Breakthrough Biology
Cloud Architecture
Proprietary Analysis
A new strategy against hard and undruggable targets
Specifically decrease or increase the production of target proteins
Translation Control Lab
Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture
Anima Lab
Cloud
• Analysis Assessment
• Bio Data Analysis
Product Pipeline
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).
Pharma Collaborations
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact partnering@animabiotech.com.
17 Scientific Collaborations
14 Publications
-
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53 -
DSCR1 is required for both axonal growth cone extension and steering
J Cell Biol. 2016; 23;213(4):451-62. -
In vivo single-RNA tracking shows that most tRNA diffuses freely in live bacteria
Nucleic Acid Res. (2017); 45 :926-937
Coverage
Blog
-
How platform companies should partner with pharma
Over the years, as Anima was still developing its technology platform, I attended many conferences in which I was selling our vision to pharma. I always received these responses; "this is so novel," "this platform has huge potential," but also heard "this is very early," "what results do you...
January 31st, 2019
News & Events
-
European High Content Screening User Group Meeting
When: May. 16th, 2019 - May. 17th, 2019
Where: Barcelona, SpainAnima Biotech has been invited to present about the discovery of Protein Synthesis Modulators of "Undruggable" Targets using its Translation Control Therapeutics platform during the European High Content Screening User Group Meeting 2019.
The European High Content Screening User Group Meeting provides a unique opportunity for users to appreciate the broad diversity of HCS applications; gain insights into new workflow solutions; share their experience, discuss challenges and learn about technology updates.
-
11th Annual International ChinaBio Partnering Forum 2019
When: May. 8th, 2019 - May. 9th, 2019
Where: Shanghai, ChinaAnima Biotech has been invited to present about its business, technology and partnering strategies during the 11thAnnual International ChinaBio Partnering Forum 2019.
The ChinaBio Partnering Forum is the premier life science partnering event in China. The event will attract biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.
-
BioCentury 26th Annual Future Leaders in the Biotech Industry Conference
When: Apr. 12th, 2019
Where: New York, USAAnima Biotech has been invited to present and participate on a panel during the BioCentury 26th Annual Future Leaders in the Biotech Industry Conference.
The Future Leaders Class of 2019 will showcase the next wave of investment opportunities in redefining disease, expanding the world of druggable targets, advancing next-generation modalities and applying AI to drug development.